GLORIA

GEOMAR Library Ocean Research Information Access

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Online Resource
    Online Resource
    Totowa, NJ :Humana Press,
    Keywords: Neoplasms--drug therapy. ; Antineoplastic Agents--pharmacology. ; Cell Cycle--drug effects. ; Cell Cycle Proteins--drug effects. ; Drug Resistance, Neoplasm. ; Electronic books.
    Description / Table of Contents: Checkpoint regulation is critical in understanding cancer development and cancer therapy. This book builds upon existing concepts of checkpoints and aims to expand our understanding of the inner workings of the critical checkpoint machinery.
    Type of Medium: Online Resource
    Pages: 1 online resource (275 pages)
    Edition: 1st ed.
    ISBN: 9781607611783
    Series Statement: Cancer Drug Discovery and Development Series
    DDC: 571.84377
    Language: English
    Note: 157687_1_En_FM1_Chapter_OnlinePDF_O.pdf -- 157687_1_En_1_Chapter_OnlinePDF_O.pdf -- Chapter 1 -- Evasion of G1 Checkpoints in Cancer -- 1.1 Introduction -- 1.2 The Molecular Core Controlling Progression Through G1 -- 1.2.1 CDKs are the Engine Behind the Cell Cycle -- 1.2.2 Cyclins are Essential Binding Partners for CDKs -- 1.2.3 CKIs Prevent Activation of CDKs -- 1.2.4 Phosphorylation and Dephosphorylation of Cyclin-CDK Complexes -- 1.3 Early G1 Checkpoint -- 1.4 The Restriction Point -- 1.5 The Stress Checkpoint -- 1.6 Hypermitogenic Arrest -- 1.7 AMPK and an Energy Checkpoint? -- 1.8 The Role of Reactive Oxygen Species in Cancer -- 1.9 Conclusions -- References -- 157687_1_En_2_Chapter_OnlinePDF_O.pdf -- Chapter 2 -- Distinct Pathways Involved in S-Phase Checkpoint Control -- 2.1 Introduction -- 2.2 Unperturbed S-Phase Fork Initiation and Progression -- 2.3 S-Phase Checkpoint Overview -- 2.3.1 The Intra-S-Phase Checkpoint -- 2.3.1.1 Molecules Involved in the Intra-S-Phase Checkpoint -- 2.3.2 The Replication Checkpoint -- 2.3.3 The S-M Checkpoint -- References -- 157687_1_En_3_Chapter_OnlinePDF_O.pdf -- Chapter 3 -- Mechanisms of G2 Phase Arrest in DNA Damage-Induced Checkpoint Response -- 3.1 Introduction -- 3.2 Checkpoint Inhibition of Cdc2/Cyclin B Activity by Multiple Mechanisms -- 3.3 Two Major Mechanisms are Critically Involved in Cdc25 Activation During G2/M Transition -- 3.3.1 Inhibition of 14-3-3 Removal During DNA Damage-Induced G2 Phase Checkpoint Response -- 3.3.2 Inhibition of Activating Phosphorylation of Cdc25 in DNA Damage-Induced G2 Phase Checkpoint Response -- 3.4 p53-Dependent Mechanisms in the DNA Damage-Induced G2 Checkpoint Response -- 3.4.1 Role of p21 -- 3.4.2 Role of 14-3-3s -- 3.4.3 Role of GADD45 -- 3.5 Weakened G2 Phase Checkpoint in Tumor Cells and Its Exploitation in Cancer Therapy -- 3.6 Conclusion -- References. , 157687_1_En_4_Chapter_OnlinePDF_O.pdf -- Chapter 4 -- Centrosomes in Checkpoint Responses -- 4.1 Centrosomes -- 4.2 Centrosomal Regulation of the G2/M Transition -- 4.2.1 Centrosomal Regulation of Unperturbed G2/M Progression -- 4.2.1.1 Cdc25 -- 4.2.1.2 Aurora-A -- 4.2.1.3 Chk1 -- 4.2.2 Centrosomal Regulation of the DNA-Damage-Induced G2/M Checkpoint -- 4.2.2.1 DNA Damage Checkpoint Network -- 4.2.2.2 Role of Centrosomes -- 4.2.2.3 Factors Impacting Centrosomal Regulation -- 4.3 DNA-Damage-Induced Centrosome Amplification -- 4.3.1 Mechanisms of DNA-Damage-induced Centrosome Amplification -- 4.3.1.1 Genetic Factors Contributing to Centrosome Amplification -- 4.3.1.2 The Process Involved in Centrosome Amplification -- 4.3.2 Consequences of DNA-Damage-induced Centrosome Amplification -- 4.3.3 Centrosome Clustering -- 4.4 Centrosome Damage Checkpoint -- References -- 157687_1_En_5_Chapter_OnlinePDF_O.pdf -- Chapter 5 -- Interplay of 14-3-3 Family of Proteins with DNA Damage-Regulated Molecules in Checkpoint Control -- 5.1 Introduction -- 5.2 p53 -- 5.3 MDM2 -- 5.4 Akt -- 5.5 Myc and miz1 -- 5.6 Chk1 and Chk2 -- 5.7 BRCA1 -- 5.8 Cell Cycle Regulators -- 5.8.1 CDC25 -- 5.8.2 CDK -- 5.8.3  CDK11 -- 5.9 Conclusion -- References -- 157687_1_En_6_Chapter_OnlinePDF_O.pdf -- Chapter 6 -- Chromatin Modifications and Orchestration of Checkpoint Response in Cancer -- 6.1 Changes in Chromatin Modification at Abnormal Chromosomal Sites -- 6.2 Recognition of Abnormal Chromatin by Sensor Proteins -- 6.3 Activation of Transducer Kinases -- 6.4 Regulation of Checkpoint Kinases -- 6.5 Effector Molecules -- 6.5.1 p53 -- 6.5.2 Cdc25 Family of Phosphatases -- 6.6 Conclusion -- References -- 157687_1_En_7_Chapter_OnlinePDF_O.pdf -- Chapter 7 -- DNA Damage Response and the Balance Between Cell Survival and Cell Death. , 7.1 DNA Damage Triggers Signaling that Stimulates DNA Repair and Apoptosis -- 7.2 The DNA Damage Response: The Mrn/Atm/Atr Connection -- 7.3 The DNA Damage Response: Cell Cycle Arrest -- 7.4 DNA Damage Response and Apoptosis Pathways -- 7.4.1 p53 -- 7.4.2 Sustained JNK and p38 Kinase Activation -- 7.4.3 Caspase-2 Activation -- 7.4.4 Survival Signaling Mediated by NF-kB -- 7.4.5 Survival Signaling Mediated by Akt -- 7.5 Conclusion -- References -- 157687_1_En_8_Chapter_OnlinePDF_O.pdf -- Chapter 8 -- Dysfunction of the RB Retinoblastoma Gene in Cancer -- 8.1 Introduction -- 8.2 The RB Family -- 8.3 RB and the Cell Cycle -- 8.3.1 The E2F Family and Its Pocket Protein-Mediated Regulation -- 8.3.2 E2F-Independent Mechanisms of Cell Cycle Regulation -- 8.4 RB and Cancer -- 8.4.1 Different Mechanisms of RB Inactivation in Cancer -- 8.4.2 RB Pathway Deregulation in Cancer -- 8.4.3 RB, Angiogenesis, and Metastasis -- 8.4.4 Mouse Models of RB Loss and Cancer -- 8.5 RB Functions Affecting Its Tumor Suppressor Role -- 8.5.1 RB and Transcriptional Activation -- 8.5.2 RB and Apoptosis -- 8.5.3 RB and Senescence -- 8.5.4 RB and Genomic Instability -- 8.6 Exploiting RB Pathway Therapeutically -- References -- 157687_1_En_9_Chapter_OnlinePDF_O.pdf -- Chapter 9 -- G1 Phase Cyclins in Cancer Development and Progression -- 9.1 Introduction -- 9.2 Identification of Cyclin D1 as a Putative Proto-oncogene -- 9.2.1 Chromosomal Translocations Associated with Cyclin D1 Overexpression -- 9.2.2 Cyclin D1 Overexpression Promotes Tumor Development -- 9.3 Impact of Deregulated Mitogenic Signaling on Cyclin D1 Expression -- 9.3.1 Mitogenic Signaling Pathways Converge on Cyclin D1 -- 9.3.2 Deregulated Wnt Signaling and Cyclin D1 in Cancer -- 9.3.3 Oestrogen Receptor Signaling and Cyclin D1 in Cancer -- 9.4 CCND1 amplification in cancer. , 9.4.1 CCND1 Amplification is Common in Cancer -- 9.4.2 Importance of CCND1 Amplification in Breast Cancer -- 9.4.3 CCND1 Amplification Plays a Limited Role in Mediating Cyclin D1 Overexpression -- 9.5 Deregulated cyclin D1 degradation is common in cancer -- 9.5.1 Cyclin D1 Degradation During the Normal Cell Cycle -- 9.5.2 Phosphorylation-Dependent Cyclin D1 Degradation -- 9.5.3 GSK3b-Independent Cyclin D1 Phosphorylation -- 9.5.3.1 Mirk/Dyrk1B -- 9.5.3.2 p38SAPK2a -- 9.5.3.3 ATM and ATR -- 9.5.3.4 IkB Kinase a -- 9.5.4 Phosphorylation- and Ubiquitylation-Independent Degradation of Cyclin D1 -- 9.5.4.1 Phosphorylation-Independent Cyclin D1 Degradation -- 9.5.4.2 Ubiquitin-Independent Cyclin D1 Degradation -- 9.5.5 Role of SCF Complexes in Regulating Cyclin D1 Stability -- 9.5.5.1 Cyclin D1 Interacts with SCF Complexes -- 9.5.5.2 Skp2/p45 -- 9.5.5.3 Fbx4 -- 9.5.5.4 Fbxw8 -- 9.5.5.5 b-TrCP -- 9.5.6 Deciphering the Interactions Between Different Cyclin D1 Degradation Pathways -- 9.6 The cyclin D1b splice variant in cancer -- 9.7 Roles of D-Type Cyclins in Cancer -- 9.7.1 Oncogenic Roles of Cyclin D1 -- 9.7.1.1 Cyclin D1 as an Oncoprotein -- 9.7.1.2 Importance of Cyclin D1 Localization in Cancer -- 9.7.1.3 CDK4/6-Independent Activity of Cyclin D1 in Cancer -- 9.7.2 Roles of Cyclin D2 and D3 in Cancer -- 9.8 Pharmacological Targeting of Cyclin D1 in Cancer -- 9.9 Cyclin E in Cancer -- References -- Chapter 9 -- G1 Phase Cyclins in Cancer Development and Progression -- 9.1 Introduction -- 9.2 Identification of Cyclin D1 as a Putative Proto-oncogene -- 9.2.1 Chromosomal Translocations Associated with Cyclin D1 Overexpression -- 9.2.2 Cyclin D1 Overexpression Promotes Tumor Development -- 9.3 Impact of Deregulated Mitogenic Signaling on Cyclin D1 Expression -- 9.3.1 Mitogenic Signaling Pathways Converge on Cyclin D1. , 9.3.2 Deregulated Wnt Signaling and Cyclin D1 in Cancer -- 9.3.3 Oestrogen Receptor Signaling and Cyclin D1 in Cancer -- 9.4 CCND1 amplification in cancer -- 9.4.1 CCND1 Amplification is Common in Cancer -- 9.4.2 Importance of CCND1 Amplification in Breast Cancer -- 9.4.3 CCND1 Amplification Plays a Limited Role in Mediating Cyclin D1 Overexpression -- 9.5 Deregulated cyclin D1 degradation is common in cancer -- 9.5.1 Cyclin D1 Degradation During the Normal Cell Cycle -- 9.5.2 Phosphorylation-Dependent Cyclin D1 Degradation -- 9.5.3 GSK3b-Independent Cyclin D1 Phosphorylation -- 9.5.3.1 Mirk/Dyrk1B -- 9.5.3.2 p38SAPK2a -- 9.5.3.3 ATM and ATR -- 9.5.3.4 IkB Kinase a -- 9.5.4 Phosphorylation- and Ubiquitylation-Independent Degradation of Cyclin D1 -- 9.5.4.1 Phosphorylation-Independent Cyclin D1 Degradation -- 9.5.4.2 Ubiquitin-Independent Cyclin D1 Degradation -- 9.5.5 Role of SCF Complexes in Regulating Cyclin D1 Stability -- 9.5.5.1 Cyclin D1 Interacts with SCF Complexes -- 9.5.5.2 Skp2/p45 -- 9.5.5.3 Fbx4 -- 9.5.5.4 Fbxw8 -- 9.5.5.5 b-TrCP -- 9.5.6 Deciphering the Interactions Between Different Cyclin D1 Degradation Pathways -- 9.6 The cyclin D1b splice variant in cancer -- 9.7 Roles of D-Type Cyclins in Cancer -- 9.7.1 Oncogenic Roles of Cyclin D1 -- 9.7.1.1 Cyclin D1 as an Oncoprotein -- 9.7.1.2 Importance of Cyclin D1 Localization in Cancer -- 9.7.1.3 CDK4/6-Independent Activity of Cyclin D1 in Cancer -- 9.7.2 Roles of Cyclin D2 and D3 in Cancer -- 9.8 Pharmacological Targeting of Cyclin D1 in Cancer -- 9.9 Cyclin E in Cancer -- References -- 157687_1_En_10_Chapter_OnlinePDF_O.pdf -- Chapter 10 -- The BRCA1/2 Pathway Prevents Some Leukemias and Lymphomas in Addition to Breast/Ovarian Cancers: Malignancies that Overcome Ch -- 10.1 Introduction -- 10.2 Methods used to Study the BRCA Pathway in Hematologic Cancers. , 10.3 Defects Impacting the BRCA Pathway in Hematologic Cancers.
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract We evaluated a novel system of complete hepatic venous isolation and chemofiltration (CHVI-CF) to reduce systemic drug exposure following regional hepatic infusion of doxorubicin. Rabbits bearing hepatic VX-2 tumors were given doxorubicin via either hepatic arterial infusion (HAI) or portal venous infusion (PVI). A dualballoon vena cava catheter and extracorporeal chemofilter were used to capture and filter hepatic venous blood in experimental animals. Control animals received chemotherapy without hepatic venous isolation and chemofiltration. Following a 5-min HAI of doxorubicin (3 or 5 mg/kg), control and experimental animals had similar doxorubicin levels in their livers and VX-2 tumors, but experimental animals showed a significant reduction in doxorubicin levels in systemic plasma, heart, and kidney tissue as compared with control animals (P〈0.01). HAI produced a 4-fold increase in doxorubicin levels in VX-2 tumors as compared with the drug levels obtained using PVI (P〈0.01). A single HAI of 3 mg/kg doxorubicin in animals treated with CHVI-CF produced marked tumor necrosis at 7 and 14 days after treatment. By increasing the total body clearance of doxorubicin, this system will allow HAI of higher doses of drug in attempts to improve the antitumor response.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    ISSN: 1432-0843
    Keywords: Chemotherapy ; TNF ; Hyperthermia ; Colon Adenocarcinoma ; Multimodality
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Effective adjunctive therapies for colorectal carcinoma are clearly needed. We evaluated the cytotoxic responses in vitro of human colon carcinoma cell lines to combined modalities: 5-fluorouracil/leucovorin (5-FU/LV), carboplatin (CP), tumor necrosis factor (TNF) and hyperthermia (HTX). Cytotoxicity was evaluated in a cell proliferation assay using crystal violet staining. 5-FU/LV was administered 2–3 days before TNF and CP, followed 1 h later by HTX. These cell lines were relatively resistant to HTX alone (42°C for 2 h), but were heterogeneous in their responses to various doses of the other single agents. This heterogeneity was also evident for combined modalities: the geneity was also evident for combined modalities: the HCT-15 cell line exhibited significant supra-additivity for selected doses of CP, TNF and 5-FU/LV, which was further enhanced by hyperthermia. In contrast, the HT-29 cell line did not demonstrate a strong pattern for supra-additivity, whereas the DLD-1 cell line had an intermediate response. Thus, our results suggest one approach to develop effective and dose-sparing multimodality therapeutic regimens for colon adenocarcinoma.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Adult female rats were treated intraperitoneally with 8 mg/kg of cis-dichlorodiammineplatinum (II). At various times after treatment 1, 3, 5, 8, 12 days replicate animals were killed and liver and kidney cytosols examined for activity of glutathione-dependent transferase activities and levels of glutathione. Hepatic levels of glutathione were depressed by 13–28% at 1, 3, 5 days after dosing. Renal levels of glutathione were increased by 3–5 fold at 8 and 12 days after drug administration. Renal levels of glutathione were decreased at nearly all times studied with a nadir at 5 days. Activity of glutathione s-acryl transferase was increased and S-epoxidetransferase was decreased at 5, 8, 12 days after dosing. When cisplatinum was added to incubation mixtures in vitro, no changes in enzyme activities were observed. When cisplatin and reduced glutathione were determined chromatographically in tissue cytosols from treated rats, 30% of the recovered platinum was associated with glutathione. In tissue cytosols, greater than 95% of the total platinum content was retained in the supernatant when protein was precipitated with trichloroacetic acid, while only 3–5% of the protein was retained.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    Electronic Resource
    Electronic Resource
    Springer
    Cancer chemotherapy and pharmacology 15 (1985), S. 307-309 
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Although mesna afforded protection against the cytotoxicity of cisplatin in Chinese hamster cells, line V-79-753B, in vitro, there was no evidence for protection against nephrotoxicity when this drug combination was examined in the rat. It seems likely that cisplatin-induced nephrotoxicity is mediated by intracellular events in kidney cells which cannot be inhibited by mesna possibly due to its presence within cells in vivo as the stable and unreactive disulphide. On the basis of these data it is unlikely that combinations of mesna and cisplatin will be of therapeutic benefit in man.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Electronic Resource
    Electronic Resource
    Springer
    Cancer chemotherapy and pharmacology 22 (1988), S. 11-16 
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary Since the reactivity of carboplatin depends on the rate of removal of the 1,1-cyclobutanedicarboxylate ligand, the time course of this dissociation has been determined in various tissue and body fluids using 14C-labelled carboplatin (cis-diammine[1,1-cyclobutane-1-14C-dicarboxylate]platinum II). Mice received 14C-carboplatin (80 mg/kg; 1.1 mCi/kg, i.v.), and tissue was removed at times ranging from 5 min to 5 days posttreatment. Following solubilization, tissue aliquots were analyzed for platinum and 14C contents. Carboplatin remained intact for up to 2 h posttreatment, since the ratio of 14C:Pt in tissues (nmol/g) was unity. Thereafter, the 14C ligand was released from the molecule and preferentially removed from tissues, indicated by decreasing 14C:Pt ratios. The elimination half-lifes for Pt varied between tissues (40–156 h). In contrast, the corresponding half-lifes for the 14C species were similar in most types of tissue (18–35 h), although those in the liver and spleen were excetpional (210 and 90 h, respectively). At 5 days a maximum of 4%–24% of the total Pt in tissue might exist as intact drug. Thus, the metabolic handling of carboplatin varies according to the tissue, since the elimination of the 14C cyclobutane dicarboxylate species from most tissue was similar and Pt elimination was slower and tissue-dependent.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    ISSN: 1432-0843
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary The pharmacokinetics of liposome-entrappedcis-bis-neodecanoato-trans-R,R-1,2-diaminocyclohexane platinum(II) (L-NDDP) and cisplatin (CDDP) were studied after i.v. and i.p. administration of an equimolar dose (11 and 5 mg/kg for L-NDDP and CDDP, respectively) in the rat. The systemic absorption following i.p. administration was faster in rats receiving CDDP than in those receiving L-NDDP. Peak serum platinum (Pt) levels were observed at 30 min and 12 h after the i.p. administration of CDDP and L-NDDP, respectively. Administration by the i.v. route did not significantly alter the serum Pt levels for either compound. However, serum Pt levels were 2–3 times greater in animals treated with L-NDDP than in those treated with CDDP. The estimated pharmacokinetic parameters for each drug were independent of the route of administration, except for the clearance (Cl) of CDDP, which increased 2-fold following i.p. administration. In addition, significant differences in pharmacokinetic parameters were observed between drug-treatment groups that were independent of the route of administration: the serum Pt area under the concentration-time curve (AUC) was higher and the volume of distribution at steady state (Vdss) was lower in rats receiving L-NDDP. Pt levels measured at 6 h in the peritoneal fluid, peritoneal tissue, and intestine of rats receiving i.p. L-NDDP were higher than those observed in rats receiving either i.v. L-NDDP or CDDP by either route. Pt levels measured in the liver and spleen of rats receiving L-NDDP were independent of the route of administration and were significantly higher than those determined in rats treated with CDDP. In contrast, kidney Pt levels were lower in rats receiving L-NDDP than in rats receiving CDDP by either route. These results suggest that the prolongation of the mean retention time of L-NDDP in the peritoneum achieved after i.p. administration without compromising the systemic distribution of the drug may result in a significant enhancement of the therapeutic efficacy of L-NDDP against malignancies confined to the peritoneal cavity as compared with that of i.p. CDDP.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    ISSN: 1432-0843
    Keywords: Key words: Hyperthermia – Cisplatin – DNA adducts
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract. An optimal scheduling of hyperthermia and cis-diammine-dichloroplatinum(II) (cisplatin) may increase the therapeutic gain of the combination of these two modalities. In this study, intracellular platinum accumulation, total platinum binding to DNA, and DNA interstrand cross-links (ISC) were assayed to investigate the molecular mechanisms responsible for the effect of sequencing hyperthermia on the thermal enhancement of cisplatin-induced cytotoxicity in mouse leukemia L1210 cells. Simultaneous treatment with heat (41.5°C, 60 min) and cisplatin produced maximal cell killing with a 4-fold decrease in the 50% growth-inhibitory concentration (IC50) of the platinum complex. Super-additive cell killing was also shown when cells were exposed to heat before cisplatin treatment, whereas no thermal enhancement in cisplatin-mediated cytotoxicity was observed in cells given heat after exposure to cisplatin. These results correlated with the degree of formation of ISC observed in cells following various treatments. A 2- to 3-fold increase in ISC formation was observed in cells given heat before or during cisplatin exposure, whereas heat after cisplatin treatment did not alter either the formation or the reversal of ISC as compared with cisplatin alone. The increased ISC formation was associated with an increase in intracellular platinum accumulation and total platinum binding to DNA in cells given heat before or during cisplatin exposure. These data, showing that hyperthermia potentiates cisplatin cytotoxicity by increasing drug uptake and the formation of DNA adducts without inhibiting the repair of DNA lesions, demonstrate the potential utility of sequencing hyperthermia combined with cisplatin as a clinical anticancer therapy.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1432-0843
    Keywords: Hyperthermia ; Cisplatin ; DNA adducts
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract An optimal scheduling of hyperthermia andcis-diammine-dichloroplatinum(II) (cisplatin) may increase the therapeutic gain of the combination of these two modalities. In this study, intracellular platinum accumulation, total platinum binding to DNA, and DNA interstrand crooslinks (ISC) were assayed to investigate the molecular mechanisms responsible for the effect of sequencing hyperthermia on the thermal enhancement of cisplatin-induced cytotoxicity in mouse leukemia L1210 cells. Simultaneous treatment with heat (41.5°C, 60 min) and cisplatin produced maximal cell killing with a 4-fold decrease in the 50% growth-inhibitory concentration (IC50) of the platinum complex. Super-additive cell killing was also shown when cells were exposed to heat before cisplatin treatment, whereas no thermal enhancement in cisplatin-mediated cytotoxicity was observed in cells given heat after exposure to cisplatin. These results correlated with the degree of formation of ISC observed in cells following various treatments. A 2-to 3-fold increase in ISC formation was observed in cells given heat before or during cisplatin exposure, whereas heat after cisplatin treatment did not alter either the formation or the reversal of ICC as compared with cisplatin alone. The increased ISC formation was associated with an increase in intracellular platinum accumulation and total platinum binding to DNA in cells given heat before or during cisplatin exposure. These data, showing that hyperthermia potentiates cisplatin cytotoxicity by increasing drug uptake and the formation of DNA adducts without inhibiting the repair of DNA lesions, demonstrate the potential utility of sequencing hyperthermia combined with cisplatin as a clinical anticancer therapy.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    ISSN: 1432-0843
    Keywords: Alicyclic mixed amine complex ; Pharmacokinetics ; Tissue distribution
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The clinical potential of mixed amine platinum(IV) complexes has been identified, and interest in this new class of antitumor agents has been heightened by demonstration of their activity in cisplatin-resistant neoplasms. These tetravalent platinum agents are expected to undergo a reductive reaction to form the corresponding platinum(II) drug prior to eliciting biological activity.cis-Ammine/cyclohexylamine-dichloroplatinum(II) is one such product that we evaluated with cisplatin in vivo, and we found the two complexes given i.v. or i.p. to have comparable activities against a solid murine fibrosarcoma. Following i.v. administration of the two compounds at equitoxic dose levels (20 mg/kg) to tumor-bearing mice, platinum levels in the plasma were consistently higher for cisplatin. Tissue platinum levels, in contrast, were comparable between the agents or higher for the mixed amine analog at the earliest (3-h) time point. The temporal profiles determined for the concentrations over 48 h were tissue-and/or drug-specific and could be described by terminalphase constants or half-lives of platinum in most tissues. In the plasma, kidney, lung, and jejunum, platinum levels arising from both compounds decayed with half-lives of 24–92 h. The terminal-phase constants of platinum determined in the heart for the two complexes were not significantly different from zero, indicative of levels remaining steady, whereas the constants were negative in the spleen, indicative of an increase in tissue drug concentration. In the tumor, liver, and testes, positive values for the decay-phase constants corresponding to half-lives of 47, 256, and 79 h, respectively, were seen with the mixed amine complex; this pattern contrasted with that found for cisplatin, for which the terminal-phase constant was either zero or negative. In vitro binding studies demonstrated the mixed amine complex to be more reactive. Thus, the presence of one ammine and one cyclohexylamine carrier ligand in the mixed amine complex, as opposed to the diammine ligands in cisplatin, leads to an increase in drug distribution and an alteration in the kinetics of tissue binding and removal of platinum.
    Type of Medium: Electronic Resource
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...